Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín
Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.
Tratamiento de enfermedades neurodegenerativas asociadas a la edad
Resumen
Tipo:
Oferta Tecnológica
Referencia:
TODE20160803001
Publicado:
08/08/2016
Caducidad:
08/08/2017
Resumen:
Dos hospitales universitarios alemanes han desarrollado un nuevo enfoque para la prevención del daño neuronal inflamatorio en el curso de la degeneración macular u otras enfermedades neurodegenerativas. Esta tecnología previene la producción de citoquinas proinflamatorias y especies reactivas de oxígeno mediante la aplicación de ácido polisiálico de bajo peso molecular (PSA-20). Los estudios in vitro han demostrado que el PSA-20 previene la activación de macrófagos y microglías e inhiben la producción de citoquinas proinflamatorias citotóxicas y especies reactivas de oxígeno. Se buscan empresas o institutos de investigación del sector farmacéutico con el fin de establecer acuerdos de investigación y licencia.
Details
Tittle:
Treatment of age-related neurodegenerative diseases
Summary:
Two German university hospitals invented a novel approach for the prevention of inflammatory neuronal damage in the course of age-related macular degeneration or other neurodegenerative diseases. The university hospitals offer a research cooperation that can be combined with a licence agreement to companies or institutes in the pharmaceutical sector.
Description:
There is no satisfactory therapy to prevent the loss of synapses, axons or neurons in neurodegenerative diseases, such as age-related macular degeneration (AMD), multiple sclerosis and Alzheimer´s disease. Several studies demonstrate that this neuronal damage is partly mediated by pro-inflammatory cytokines and reactive oxygen species released by tissue macrophages and microglia.
The present invention of two German university hospitals prevents the production of pro-inflammatory cytokines and reactive oxygen species through the application of low molecular weight polysialic acid PSA-20.
In vitro studies showed that PSA-20 prevents the activation of human macrophages and human microglia thereby inhibiting the production of cytotoxic pro-inflammatory cytokines and reactive oxygen species. It has been shown, that this anti-inflammatory effect is mediated through the human lineage specific receptor Siglec-11. Furthermore, in vivo studies revealed that the administration of PSA-20 suppresses the activation of retinal microglia and the vascular leakage in an animal model of AMD and reduces the disease symptoms in an animal model of multiple sclerosis. Thus, PSA-20 represents an ideal candidate for the treatment of neurodegenerative diseases of the brain and retina.
The university hospitals offer a research cooperation that can be combined with a licence agreement to companies or institutes in the pharmaceutical sector. The research cooperation will be dedicated to enhance the PSA-20 treatment of dry AMD.
The present invention of two German university hospitals prevents the production of pro-inflammatory cytokines and reactive oxygen species through the application of low molecular weight polysialic acid PSA-20.
In vitro studies showed that PSA-20 prevents the activation of human macrophages and human microglia thereby inhibiting the production of cytotoxic pro-inflammatory cytokines and reactive oxygen species. It has been shown, that this anti-inflammatory effect is mediated through the human lineage specific receptor Siglec-11. Furthermore, in vivo studies revealed that the administration of PSA-20 suppresses the activation of retinal microglia and the vascular leakage in an animal model of AMD and reduces the disease symptoms in an animal model of multiple sclerosis. Thus, PSA-20 represents an ideal candidate for the treatment of neurodegenerative diseases of the brain and retina.
The university hospitals offer a research cooperation that can be combined with a licence agreement to companies or institutes in the pharmaceutical sector. The research cooperation will be dedicated to enhance the PSA-20 treatment of dry AMD.
Advantages and Innovations:
This invention, the application of PSA-20, is a novel approach for the prevention of inflammatory neuronal damage caused neurodegenerative diseases of the brain and retina.
The use of PSA-20 prevents:
- the production of reactive oxygen species and of pro-inflammatory cytokines
- the activation of microglia and the vascular leakage in an animal model of age related macular degeneration
- disease symptoms in an animal model of multiple sclerosis.
In addition to that PSA-20 has a relative high therapeutic index on cultured human cells.
The use of PSA-20 prevents:
- the production of reactive oxygen species and of pro-inflammatory cytokines
- the activation of microglia and the vascular leakage in an animal model of age related macular degeneration
- disease symptoms in an animal model of multiple sclerosis.
In addition to that PSA-20 has a relative high therapeutic index on cultured human cells.
Stage of Development:
Under development/lab tested
IPs:
Secret Know-how
Partner sought
Type and Role of Partner Sought:
The university hospitals offer a research cooperation that can be combined with a licence agreement to companies or institutes in the pharmaceutical sector. The research cooperation will be dedicated to enhance the PSA-20 treatment of dry AMD.
Client
Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German
German
Keywords
Technology Keywords:
06002002 Biología celular y molecular
06001014 Neurología, investigación cerebral
06001015 Productos farmacéuticos / medicamentos
06001014 Neurología, investigación cerebral
06001015 Productos farmacéuticos / medicamentos
een_ader
